What is Wild Microbes?
Wild Microbes operates at the intersection of biotechnology and industrial manufacturing. Based in Cambridge, Massachusetts, the company provides specialized fermentation services that utilize precision gene editing to enhance microbial performance. By engineering microorganisms to act as efficient biological factories, Wild Microbes enables the production of high-value compounds, proteins, and materials that are critical to the future of cellular agriculture and sustainable chemistry. Their market position is defined by a commitment to technical excellence and the ability to provide scalable, reproducible fermentation processes for a diverse range of enterprise partners.
How much funding has Wild Microbes raised?
Wild Microbes has raised a total of $3.3M across 1 funding round:
Other Financing Round
$3.3M
Other Financing Round (2023): $3.3M with participation from Fall Line Capital, Climate Capital, Agronomics, and FreeFlow Ventures
Key Investors in Wild Microbes
Agronomics
Agronomics Limited is a leading London-listed company focusing on investment opportunities within the field of cellular agriculture, utilizing biotechnology and synthetic biology to produce proteins and fats.
Fall Line Capital
Fall Line Capital specializes in redefining investment in farmland and technology, focusing on enhancing land productivity through innovative and practical agricultural strategies.
Climate Capital
Climate Capital specializes in the investment and management of renewable energy projects, providing sustainable income and capital growth through behind-the-meter energy solutions.
What's next for Wild Microbes?
Looking ahead, the infusion of capital will likely be directed toward expanding the company's R&D infrastructure and increasing its fermentation capacity to meet growing demand from the cellular agriculture and biotech sectors. As the industry shifts toward more sustainable production models, Wild Microbes is poised to become a central node in the supply chain for bio-manufactured goods. Strategic priorities will likely include the refinement of their gene-editing toolkits to improve yield and cost-efficiency, alongside the development of new partnerships with global food and chemical manufacturers seeking to integrate synthetic biology into their core operations.
See full Wild Microbes company page
